Parkinson Disease is a debilitating neurological disorder for which there is not yet a cure. Researchers are hoping to find substances that significantly reduce the progression of the disease symptoms. Right now the main treatment is L-dopa supplementation, which can manage symptoms for day to day function, but does not prevent deterioration. However, a pilot study published in the medical journal, Neurology, in March of 2006 indicates that two substances, a synthetic antibiotic and a natural supplement, may halt the decline in neurological function.
Clinicians in the past had noticed that patients with Parkinson Disease who were taking minocycline and creatine for other health conditions, experienced a slower progression of their disease. So, researchers conducted a double-blind, randomized study as a Phase II clinical trial. Two hundred patients with a diagnosis of Parkinson Disease for no longer than 5 years and did not require medications to manage their symptoms were enrolled. They were divided into 3 groups, either given the antibiotic minocycline, creatine or placebo.
The results showed that both creatine and minocycline were deemed valid for study in Phase III clinical trials to determine if they alter the long term progression of Parkinson disease. Tolerability was rated at 91% for creatine and 77% for minocycline. Researchers suggest that these substances may fight inflammation and combat cellular stress. These findings are promising and the results of the Phase III trials are anxiously anticipated.
Posted by Dr. Jennifer Stagg on July 14, 2006 02:21 PM
